Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, ...

The findings mean that for those using preexposure prophylaxis with gender-affirming hormone therapy or long-acting hormonal ...

Bristol Myers Squibb today announced the presentation of data from its cardiovascular portfolio at the American Heart Association's Scientific Sessions 2025, taking place November 7?10, 2025 in New ...